Franchimont N, Putzeys V, Colette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004; 20: 607-14.
Ryan BM, Russel M, Schurgers L, et al. Effect of anti-tumour necrosis factor alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004; 20: 851-7.
Varghese S, Wyzga N, Griffiths AM, et al. Effects of serum from children with newly diagnosed Crohn's disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 2002; 35: 641-8.
Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998; 13: 1124-33.
Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 6: S2-17.
Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-TNFalpha treatment. Ann Rheum Dis 2005; January 7 (Epub ahead of print).
Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-κB (RANK) ligand, its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138: 491-8.
